The diagnosis of schizophrenia prodrome is significant since early intervention may prevent the development of full-blown schizophrenia. With increasing evidence indicating that glutamate is involved in the incidence of schizophrenia, we hypothesize that glutamate could be an imaging biomarker in the diagnosis of prodromal schizophrenia. We applied the glutamate CEST imaging technique in schizophrenic models and demonstrates that glutamate changes in different regions of the brain at an early stage, which may provide a powerful indicator of the diagnosis of schizophrenia prodrome. In addition, the glutamate CEST image had excellent correlation with standard MR spectroscopy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords